Piramal Pharma Ltd Upgraded to Sell on Technical Improvements Despite Financial Challenges

Quality Assessment: Persistent Financial Struggles

The quality parameters for Piramal Pharma continue to reflect significant challenges. The company reported a disappointing financial performance in the second quarter of FY25-26, with Profit Before Tax (PBT) excluding other income plunging to a loss of ₹111.78 crores, marking a steep decline of 340.0% compared to the previous four-quarter average. Similarly, Profit After Tax (PAT) fell sharply by 613.2% to a loss of ₹99.22 crores, while net sales declined by 10.5% to ₹2,043.72 crores.

These results underscore the company’s ongoing difficulties in generating consistent profitability. The average Return on Equity (ROE) stands at a meagre 0.32%, indicating very low returns for shareholders. Additionally, the company’s ability to service debt remains weak, with a high Debt to EBITDA ratio of 3.83 times, signalling elevated financial risk. Although net sales have grown at a modest annual rate of 9.15% over the past five years, this growth has not translated into robust profitability or cash flow generation.

Valuation: Fair but Discounted Relative to Peers

From a valuation standpoint, Piramal Pharma is currently trading at a fair level, supported by a Return on Capital Employed (ROCE) of 2.7% and an Enterprise Value to Capital Employed ratio of 2.2. These metrics suggest that the stock is reasonably priced relative to the capital it employs in its operations. Moreover, the stock is trading at a discount compared to the historical valuations of its pharmaceutical peers, which may offer some appeal to value-oriented investors.

However, the company’s long-term growth prospects remain subdued, and the recent sharp decline in profitability—profits have fallen by 158.7% over the past year—raises concerns about sustainable earnings recovery. The stock’s 52-week high of ₹273.20 contrasts starkly with its current price near ₹170.15, reflecting significant market scepticism.

Financial Trend: Mixed Signals with Negative Profitability

While the company’s operating profit has grown at a healthy annual rate of 23.29% over the long term, this has not been sufficient to offset the sharp declines in net profitability. The recent quarterly results highlight a deteriorating earnings trend, with losses widening significantly. This negative financial trajectory is reflected in the stock’s performance, which has delivered a negative return of 34.09% over the past year, underperforming the BSE Sensex’s positive 8.51% return over the same period.

Over three years, Piramal Pharma has generated a cumulative return of 51.79%, slightly outperforming the Sensex’s 40.02% gain, but this longer-term outperformance is overshadowed by recent weakness. The stock’s one-month and one-week returns have also been notably negative at -7.93% and -3.92%, respectively, compared to the Sensex’s modest declines of -0.53% and -0.26%.

Technicals: Improvement Spurs Upgrade

The primary catalyst for the upgrade from Strong Sell to Sell is a shift in technical indicators, signalling a mild easing of bearish momentum. The technical grade has improved as the overall trend moved from bearish to mildly bearish. Weekly and monthly Moving Average Convergence Divergence (MACD) indicators remain bearish and mildly bearish, respectively, but other technical signals offer a more nuanced picture.

The Relative Strength Index (RSI) on both weekly and monthly charts shows no clear signal, while Bollinger Bands indicate a bearish trend weekly but sideways movement monthly. Daily moving averages continue to be bearish, but the Dow Theory weekly trend has turned mildly bullish, and the On-Balance Volume (OBV) weekly indicator is mildly bullish as well. These mixed signals suggest that while the stock remains under pressure, some technical support is emerging.

Price action remains subdued, with the stock trading near its 52-week low of ₹165.05 and closing at ₹170.15 on 2 January 2026, down 1.25% from the previous close. The intraday range on the latest trading day was ₹169.55 to ₹173.20, indicating limited volatility.

Institutional Interest and Market Positioning

Institutional investors hold a significant stake in Piramal Pharma, with 45.17% ownership. This level of institutional interest suggests that sophisticated market participants continue to monitor the company closely, potentially providing some stability amid volatility. These investors typically have greater resources to analyse fundamentals and may be positioning for a turnaround or value opportunity despite current challenges.

Summary and Outlook

Piramal Pharma’s upgrade from Strong Sell to Sell reflects a cautious optimism driven by technical improvements, even as fundamental challenges persist. The company’s weak profitability, high leverage, and recent negative earnings trends weigh heavily on its quality and financial trend assessments. Valuation metrics suggest the stock is fairly priced and discounted relative to peers, but this alone is insufficient to warrant a more positive rating.

Investors should weigh the mild technical recovery against the company’s ongoing operational and financial headwinds. The stock’s underperformance relative to the broader market over the past year and recent quarters highlights the risks involved. However, the presence of substantial institutional holdings and some stabilising technical indicators may provide a foundation for potential recovery if financial performance improves.

Given the current data, the Sell rating indicates that while the stock is no longer a strong sell, it remains a cautious proposition for investors seeking value in the Pharmaceuticals & Biotechnology sector.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year (MRP = Rs. 34,999) Start Saving Now →